BioSpace News Archive

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:00 p.m. ET.

Novavax, Inc. (Nasdaq: NVAX),today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness endpoint in the pediatric expansion of its PREVENT-19 pivotal Phase 3 trial and demonstrated 80% efficacy overall at a time when the Delta variant was the predominant circulating strain in the U.S.

Illumina, Inc. announced its financial results for the fourth quarter and fiscal year 2021, which include the consolidated financial results of GRAIL.

Personalis, Inc., a leader in advanced genomics for cancer, announced that it will release its fourth quarter and full-year 2021 financial results on Thursday, February 24, 2022.

Telix Pharmaceuticals Limited announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC for highly pure no-carrier-added lutetium-177, a therapeutic isotope used in Telix’s portfolio of molecularly targeted radiation investigational products.

ObsEva SA (NASDAQ: OBSV; SIX: OBSN), today announced a strategic licensing agreement with Theramex, a leading global pharmaceutical company specializing in women’s health, to support the commercialization and market introduction of linzagolix across global markets outside of the U.S., Canada and Asia.

DexCom, Inc. reported its financial results as of and for the quarter and fiscal year ended December 31, 2021.

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter 2021 and year end 2021 financial results on Wednesday, February 23, 2022, before the open of the US financial markets.

AN2 Therapeutics, Inc., today announced topline results from its Phase 1b dose-ranging study of oral epetraborole. AN2 Therapeutics is developing epetraborole.

OpGen, Inc. announced the release of a new peer-reviewed journal publication that demonstrates that the Acuitas® AMR Gene Panel accurately detects and differentiates 28 genetic antimicrobial resistance markers performed on isolated colonies from 26 different pathogens.